Established in 2013, Rekah’s R&D division has labs with advanced equipment that enable it to develop and license new products.
Our three primary types of R&D projects are:
- formulating generics
- developing combination therapeutic entities
- upgrading dossiers to eCTD format
Our R&D division focuses on two core areas:
- unique tablets, mainly steroids
- ophthalmic products
The group's R & D program includes accelerating the development and registration of corticosteroid preparations.
In March 2022, the Rekach Group inaugurated a new and advanced R&D center in Kfar Saba, Israel.